GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Net Margin %

Oruka Therapeutics (FRA:HQ1) Net Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Oruka Therapeutics's Net Income for the six months ended in Dec. 2024 was €0.00 Mil. Oruka Therapeutics's Revenue for the six months ended in Dec. 2024 was €0.00 Mil. Therefore, Oruka Therapeutics's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Oruka Therapeutics's Net Margin % or its related term are showing as below:


FRA:HQ1's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -119.77
* Ranked among companies with meaningful Net Margin % only.

Oruka Therapeutics Net Margin % Historical Data

The historical data trend for Oruka Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Net Margin % Chart

Oruka Therapeutics Annual Data
Trend Dec24
Net Margin %
-

Oruka Therapeutics Semi-Annual Data
Dec24
Net Margin % -

Competitive Comparison of Oruka Therapeutics's Net Margin %

For the Biotechnology subindustry, Oruka Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Net Margin % falls into.


;
;

Oruka Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Oruka Therapeutics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=0/0
= %

Oruka Therapeutics's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics  (FRA:HQ1) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Oruka Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Net Margin %
Comparable Companies
PGEN CGEM MNMD VERV RLAY PHAT TBPH OMER AUTL CRMD VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ORKA:USA
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Website
https://www.orukatx.com
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines